Analyst Reco. MaxCyte, Inc.

Equities

MXCT

US57777K1060

Delayed London S.E. Other stock markets 04:05:57 2024-04-25 am EDT			5-day change	1st Jan Change
307 ^GBX	+0.66%		-1.92%	-12.91%

Apr. 02	MaxCyte inks deal with Be Bio; Orcadian firms farmout	AN
Apr. 02	MaxCyte, Inc. Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BTIG Adjusts Price Target on MaxCyte to $8 From $10, Maintains Buy Rating	Mar. 13	MT
Craig-Hallum Starts Coverage on MaxCyte with Buy Rating, $7 Price Target	Nov. 29	MT
Interest Rate Worries, Jobs Outlook Leave Exchange-Traded Funds, Equity Futures Mixed Premarket Thursday	23-10-05	MT
BTIG Adjusts MaxCyte's Price Target to $11 From $10, Reiterates Buy Rating	22-08-15	MT
Stifel Nicolaus Adjusts Price Target for MaxCyte tp $16 From $18, Maintains Buy Rating	22-05-10	MT
FTSE Edges Lower, March Inflation Data Seen Securing Another BoE Rate Rise in May	22-04-13	DJ
FTSE Down, BOE's Inflation, Interest-Rate Outlook Key For Long-Dated Gilts	21-11-03	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

fermer